Optimized for the ex vivo activation and expansion of regulatory T cells (Tregs), CTS Dynabeads Treg Xpander provides more specific and higher fold expansion compared to our CTS Dynabeads CD3/CD28. Tregs activated and expanded with this product show suppressive activity and display the characteristic Treg cytokine profile and phenotype. Furthermore, high stability of the expanded Tregs has been demonstrated through analysis of the Treg-specific demethylated region.

CTS Dynabeads Treg Xpander features include:
• Aseptically manufactured and ready for clinical trials and cell therapy manufacturing process development
• Drug Master File (DMF) to cross-reference in IND applications
• >800 fold expansion after two stimulations
• Treg phenotype (FOXP3) and suppressive function maintained

Regulatory T cells (CD4+ CD25+ FOXP3+) are a suppressive subset of CD4+ T helper cells and are important for the regulation of immune responses. Due to a relative frequency of 1–2% of the total lymphocyte population, ex vivo expansion of Tregs prior to adoptive transfer is expected for most clinical applications.